# SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

> **NCT05570825** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Lung Non-Small Cell Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** CXCR1/2 Inhibitor SX-682
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT05570825
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-06
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05570825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05570825, "SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05570825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*